Skip to main content
x

Recent articles

TuHura makes its bid for Merkel accelerated approval

The company reckons its immunotherapy could improve on Keytruda.

Revolution mortgages royalties for more cash

“We need all the capital we can get our hands on," the company states.

Nuvalent loses ground in the front line

Zidesamtinib is having a hard time catching up with Ibtrozi's line-agnostic approval.

Better late than never for Datroway in lung cancer

Astra/Daiichi have trumped Gilead’s Trodelvy with a lung cancer approval.

Exelixis claims a next-generation colorectal win

Zanzalintinib prevails in all comers, but full data will show if the win was driven by a subgroup.

Lunsumio steps into Columvi territory

Sunmo succeeds in a setting very similar to Starglo's.